Trials / Unknown
UnknownNCT01740271
A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients
Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- AHS Cancer Control Alberta · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Epirubicin is a common chemotherapy medication used in the treatment of breast cancer. However, chemotherapy dosing is calculated based on people's height and weight, which may not be the most accurate way. The purpose of this study is to see if epirubicin dosing based on people's genetic profiles is better than the usual methods.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epirubicin |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2015-06-01
- Completion
- 2025-06-01
- First posted
- 2012-12-04
- Last updated
- 2014-10-02
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01740271. Inclusion in this directory is not an endorsement.